

Masayuki Imagawa was appointed the acting Chief Executive of the Japanese Association of Vaccine Industries (JAVI) in June 2020. He has been VP and Head, Japan Vaccine Business Unit, Global Vaccine Business Unit, Takeda Pharmaceutical Co., Ltd. since Oct 1<sup>st</sup> in 2020. He also serves as acting board member of the Public Foundation of the Vaccine Research Center since June 2018 and has previously served board member of the Japan Antibiotics Research Association. In addition, he has joined the Resilience Japan Initiative (WG15) and also the Advisory Board of introducing an International Solidarity Levy to Japan for the Ministry of Foreign Affairs. He holds a Bachelor degree and a Master's degree in Pharmaceutical Sciences from the Osaka University of Pharmaceutical Sciences and the Tokushima University respectively, along with an MBA from Kobe University.